North Immunology to go public via reverse merger, targeting eczema with bispecific antibody
North Immunology, a private biotech incubated by ADAR1 Capital Management, announced it will become a public company through a reverse merger with Nasdaq‑listed Aethlon Medical.
The merged entity will center on North's pipeline of bispecific antibodies for inflammatory diseases, led by the half‑life extended anti‑IL‑13/anti‑IL‑18 candidate NOR‑101.
The company plans to initiate clinical testing of NOR‑101 in the first months of next year, with interim data expected mid‑year and Phase 2b results projected for 2028.
By aiming to block both type 2 and non‑type 2 inflammation pathways, the approach seeks to complement existing IL‑13 therapies such as Dupixent and Ebglyss.
This writeup was produced by pharmadog from original reporting by Fierce Biotech.
Original headline: “North Immunology goes public via reverse merger as eczema drug heads toward clinic”
read at Fierce Biotech ↗
comments(0)
5-min edit window · permanent after that